DDInter458 DDInter1677
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared specifically for each patient. In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data). Sipuleucel-T is marketed under the brand name Provenge by Dendreon Corporation. Sipuleucel-T was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC). The treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014.
Cyclosporine {u} (Compound) treats {v} (Disease) rheumatoid arthritis
rheumatoid arthritis {u} (Disease) is treated by {v} (Compound) Triamcinolone
Triamcinolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sipuleucel-T
Cyclosporine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Triamcinolone
Triamcinolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sipuleucel-T
Cyclosporine {u} (Compound) upregulates {v} (Gene) CDKN1A
CDKN1A {u} (Gene) is upregulated by {v} (Compound) Triamcinolone
Triamcinolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sipuleucel-T
Cyclosporine {u} (Compound) upregulates {v} (Gene) NFIL3
NFIL3 {u} (Gene) is downregulated by {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sipuleucel-T
Cyclosporine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Cabazitaxel
Cabazitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sipuleucel-T
Cyclosporine {u} (Compound) downregulates {v} (Gene) RGS2
RGS2 {u} (Gene) is upregulated by {v} (Compound) Triamcinolone
Triamcinolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sipuleucel-T
Cyclosporine {u} (Compound) downregulates {v} (Gene) RGS2
RGS2 {u} (Gene) is downregulated by {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sipuleucel-T
Cyclosporine {u} (Compound) upregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sipuleucel-T
Cyclosporine {u} (Compound) downregulates {v} (Gene) HAT1
HAT1 {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sipuleucel-T
Cyclosporine {u} (Compound) upregulates {v} (Gene) MYC
MYC {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sipuleucel-T
Cyclosporine (Compound) treats rheumatoid arthritis (Disease) and rheumatoid arthritis (Disease) is treated by Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Cyclosporine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Cyclosporine (Compound) upregulates CDKN1A (Gene) and CDKN1A (Gene) is upregulated by Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Cyclosporine (Compound) upregulates NFIL3 (Gene) and NFIL3 (Gene) is downregulated by Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Cyclosporine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cabazitaxel (Compound) and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Cyclosporine (Compound) downregulates RGS2 (Gene) and RGS2 (Gene) is upregulated by Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Cyclosporine (Compound) downregulates RGS2 (Gene) and RGS2 (Gene) is downregulated by Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Cyclosporine (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Cyclosporine (Compound) downregulates HAT1 (Gene) and HAT1 (Gene) is downregulated by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Cyclosporine (Compound) upregulates MYC (Gene) and MYC (Gene) is downregulated by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T